Reshaping the HIV treatment and prevention landscape

Consistent delivery of competitive launches Trelegy US: Weekly TRX Volume 18,000 16,000 14,000 12,000 10,000 8,000 6,000 4,000 2,000 1 3 5 7 9 111315171921232527293133353739414345474951 Trelegy Breo Anoro Competitor 1 Competitor 2 Source: IQVIA US weekly Rx Blenrep Cumulative US Sales 70 60 50 $M (USD) 30 30 40 20 10 Shingrix Vaccine doses post launch 1200 1000 800 600 400 200 0 0 Launch Qtr (LQ) LQ+1 LQ+2 BLENREP (Aug 2020) Competitor 1 (Jul 2019) Competitor 2 (Mar 2020) Shingrix Competitor M7 을을 First 12 months post launch Source: IQVIA BrandImpact Report - week ending March 26th Source: IQVIA NSP (doses) data M10 M11 M12 33 gsk

View entire presentation